Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:ABPNYSE:ANVSNASDAQ:APLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.09+2.0%$1.73$1.21▼$3.81$51.62M0.68265,792 shs993,501 shsABPAbpro$0.21-0.1%$0.24$0.15▼$13.00$12.69M-0.034.94 million shs3.03 million shsANVSAnnovis Bio$2.61-3.3%$2.04$1.11▼$17.88$50.66M1.62744,234 shs371,126 shsAPLTApplied Therapeutics$0.34-2.2%$0.39$0.30▼$10.62$48.55M1.863.39 million shs1.24 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+1.95%+6.63%+8.57%+1.95%+29.81%ABPAbpro0.00%-2.93%-9.26%-54.27%+20,869,900.00%ANVSAnnovis Bio0.00%-7.21%+28.04%+47.99%-50.81%APLTApplied Therapeutics0.00%-3.14%-16.37%-40.17%-92.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.6133 of 5 stars1.00.00.00.01.12.51.3ABPAbproN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio2.2084 of 5 stars3.51.00.00.02.81.70.6APLTApplied Therapeutics4.1703 of 5 stars3.33.00.04.71.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-20.26% DownsideABPAbpro 3.00Buy$4.001,816.63% UpsideANVSAnnovis Bio 3.00Buy$30.251,058.12% UpsideAPLTApplied Therapeutics 2.50Moderate Buy$6.101,678.94% UpsideCurrent Analyst Ratings BreakdownLatest ABP, ANVS, AADI, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M2.06N/AN/A$4.29 per share0.49ABPAbpro$180K70.48N/AN/A($0.29) per share-0.72ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AAPLTApplied Therapeutics$460K105.54N/AN/A$0.49 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)ABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/AANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)APLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)Latest ABP, ANVS, AADI, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AABPAbproN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ABPAbproN/A0.110.11ANVSAnnovis BioN/A10.6810.68APLTApplied TherapeuticsN/A3.003.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ABPAbpro23.30%ANVSAnnovis Bio15.83%APLTApplied Therapeutics98.31%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ABPAbpro20.80%ANVSAnnovis Bio20.80%APLTApplied Therapeutics1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableABPAbpro1560.79 million48.14 millionN/AANVSAnnovis Bio319.49 million15.43 millionOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableABP, ANVS, AADI, and APLT HeadlinesRecent News About These CompaniesApplied Therapeutics Announces Key Leadership AppointmentsJune 17, 2025 | globenewswire.comApplied Therapeutics (NASDAQ:APLT) and MEI Pharma (NASDAQ:MEIP) Critical ContrastJune 15, 2025 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Given Average Rating of "Moderate Buy" by BrokeragesJune 13, 2025 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Receives Average Rating of "Moderate Buy" from AnalystsJune 8, 2025 | marketbeat.comMillennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)June 5, 2025 | marketbeat.comApplied Therapeutics, Inc. (NASDAQ:APLT) Short Interest UpdateJune 3, 2025 | marketbeat.comJanus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT)May 27, 2025 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Raised to "Sell" at StockNews.comMay 24, 2025 | marketbeat.comApplied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage TrialMay 20, 2025 | biospace.comNew top-line data from Phase II/III trial of govorestat in CMT-SORDMay 20, 2025 | thepharmaletter.comApplied announces INSPIRE Phase 2/3 trial primary endpoint not significantMay 18, 2025 | msn.comApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 18, 2025 | globenewswire.comApplied Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comApplied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 9, 2025 | globenewswire.comWhy Applied Therapeutics, Inc.’s (APLT) Stock Is Down 6.65%May 6, 2025 | aaii.comNET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff MotionApril 22, 2025 | globenewswire.comWilliam Blair Sticks to Its Hold Rating for Applied Therapeutics (APLT)April 15, 2025 | markets.businessinsider.comApplied Therapeutics (APLT) Gets a Hold from RBC CapitalApril 15, 2025 | markets.businessinsider.comApplied Therapeutics reports FY24 EPS (76c), consensus ($1.33)April 15, 2025 | markets.businessinsider.comApplied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial ResultsApril 15, 2025 | markets.businessinsider.comApplied Therapeutics files Form 12b-25 with SECApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABP, ANVS, AADI, and APLT Company DescriptionsAadi Bioscience NASDAQ:AADI$2.09 +0.04 (+1.95%) As of 06/20/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Abpro NASDAQ:ABP$0.21 0.00 (-0.14%) As of 06/20/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Annovis Bio NYSE:ANVS$2.61 -0.09 (-3.26%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$2.73 +0.12 (+4.52%) As of 06/20/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Applied Therapeutics NASDAQ:APLT$0.34 -0.01 (-2.17%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.90%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
